CYP1A2, CYP2D6, and CYP2C19 metabolize fluvoxamine and its therapeutic concentrations could be significantly impacted by varying miR-155 levels, which differ between young, healthy individuals and older individuals with co-morbidities in COVID-19. The gene discussed is CYP2C19; the disease is COVID-19.